Management of Disseminated Intravascular Coagulation (DIC)

Core Management Algorithm

• The International Society on Thrombosis and Haemostasis (ISTH) recommends treating the underlying disease process as the cornerstone of therapy for DIC, addressing the root cause of the coagulopathy 1, 2
• In cancer-associated DIC, the ISTH guidelines suggest initiating appropriate cancer therapy immediately, such as chemotherapy, surgery, or radiation as indicated 1, 2
• For acute promyelocytic leukemia, early initiation of all-trans retinoic acid achieves good resolution of DIC, as recommended by the ISTH 3
• In sepsis-associated DIC, source control and appropriate antibiotics are essential, according to the ISTH guidelines 4

Classification and Management of DIC Subtypes

• The ISTH classifies DIC into three distinct forms: procoagulant DIC (thrombosis predominates), hyperfibrinolytic DIC (bleeding predominates), and subclinical DIC, each requiring different management approaches 5, 6
• Procoagulant DIC is common in pancreatic cancer and adenocarcinomas, presenting with arterial ischemia, venous thromboembolism, or microvascular thrombosis, as described by the ISTH 5, 7, 6
• Hyperfibrinolytic DIC is typical of acute promyelocytic leukemia and metastatic prostate cancer, presenting with widespread bleeding from multiple sites, according to the ISTH 5, 7, 6

Supportive Hemostatic Measures

• The ISTH recommends maintaining a platelet count >50×10⁹/L through platelet transfusions for active bleeding 3, 4, 8
• For prolonged coagulation times, the ISTH suggests administering 15-30 mL/kg of fresh frozen plasma (FFP) 3, 4, 8
• The ISTH recommends replacing fibrinogen with cryoprecipitate or fibrinogen concentrate if levels remain <1.5 g/L despite FFP 3, 4, 8

Anticoagulation Strategy

• The ISTH recommends initiating prophylactic anticoagulation with heparin in all patients except those with hyperfibrinolytic DIC, unless contraindications exist 1, 2, 9, 3
• The ISTH suggests using low molecular weight heparin (LMWH) as the first choice for most patients 3
• The ISTH recommends escalating to therapeutic-dose anticoagulation if arterial or venous thrombosis develops 1, 2, 9

Monitoring and Special Clinical Scenarios

• The ISTH recommends monitoring complete blood count and coagulation screen (including fibrinogen and D-dimer) regularly, with frequency ranging from daily in acute severe DIC to monthly in chronic stable DIC 10, 7, 3
• A 30% or greater drop in platelet count is diagnostic of subclinical DIC, even when absolute values remain normal, according to the ISTH 10, 7, 8
• The ISTH suggests considering temporary IVC filter placement in patients who cannot be anticoagulated but have proximal lower limb thrombosis likely to embolize 1, 2

Management of Disseminated Intravascular Coagulation (DIC) in the ICU

Diagnostic Approach

• The International Society on Thrombosis and Haemostasis (ISTH) recommends using a two-step sequential screening approach to identify patients who will benefit from specific therapies, first screening for Sepsis-Induced Coagulopathy (SIC) using the ISTH SIC score (≥4 points indicates SIC), and then applying the ISTH overt DIC score (≥5 points indicates overt DIC) for patients with more advanced coagulopathy 11, 12
• The ISTH scoring components include platelet count, PT ratio, fibrinogen, D-dimer/FDP, and SOFA score (for SIC) 11, 12
• Sequential screening on ICU admission day and 2 days later is associated with lower mortality 11

Anticoagulation Strategy Details

• Anticoagulant therapy may improve outcomes specifically in septic patients with coagulopathy or DIC, though evidence remains controversial 11, 12
• The ISTH suggests that patients with advanced overt DIC may have illness progression no longer amenable to anticoagulant therapy benefit 11

Guidelines for Management of Disseminated Intravascular Coagulation (DIC)

Anticoagulation Strategies

• Prophylactic heparin should be started in all patients with cancer‑associated DIC, except when the DIC phenotype is hyper‑fibrinolytic or when contraindications exist (platelet count < 20 × 10⁹/L or active bleeding). 13, 14
• Therapeutic‑dose anticoagulation is indicated when any of the following occur: arterial or venous thromboembolism, severe purpura fulminans with acral ischemia, vascular skin infarction, or cancer‑related DIC with documented thrombotic events. The escalation to therapeutic dosing should be based on the clinical manifestation rather than isolated laboratory abnormalities. 13, 14

Special Clinical Scenarios

• When thrombosis coexists with severe thrombocytopenia (platelet count approximately 25–50 × 10⁹/L), three management options are described:
  Choice should balance bleeding risk against thrombotic risk for the specific anatomic site. 13, 14

Agents to Avoid

• Tranexamic acid should not be used routinely in DIC because it may increase thrombotic events; it is reserved only for therapy‑resistant bleeding in hyper‑fibrinolytic DIC phenotypes. 13, 14
• Recombinant factor VIIa is not recommended; its clinical benefit remains uncertain and it carries a definite risk of inducing thrombosis. 13, 14
• Inferior vena cava (IVC) filters should be avoided except in highly selected patients who cannot receive anticoagulation and have proximal lower‑limb thrombosis at high risk of embolization; in such cases, temporary filters may be considered. 13, 14

Management of Biochemical DIC Without Bleeding

1. Treat the Underlying Trigger First

• Prompt identification and treatment of the disease causing DIC is the primary therapeutic priority, superseding all other interventions. 15
• In patients with cancer‑associated DIC, immediate initiation of disease‑directed therapy (e.g., chemotherapy, surgery, or radiation) is recommended. 15

2. Anticoagulation Strategy for Biochemical DIC

• Prophylactic‑dose heparin should be started in all non‑bleeding patients with laboratory‑only DIC, except when the phenotype is hyper‑fibrinolytic. 15
• Contra‑indications to prophylactic anticoagulation include a markedly low platelet count (e.g., <20 × 10⁹/L) or any active bleeding. 15
• Isolated prolongation of PT/aPTT does not preclude prophylactic anticoagulation in the absence of bleeding, because DIC represents a re‑balanced hemostatic state. 16

3. Choice of Heparin Agent

• Low‑molecular‑weight heparin (LMWH) is the preferred agent for most patients with biochemical DIC. 16
• Unfractionated heparin (UFH) is preferred when the patient has a high bleeding risk and renal impairment, owing to its rapid reversibility and short half‑life. 16
• In solid‑tumor‑associated DIC with documented venous thromboembolism, a 6‑month course of therapeutic‑dose LMWH (full dose for the first month, then 75 % of full dose for the remaining five months) is superior to warfarin. 16

4. Monitoring and Follow‑Up

• Routine monitoring should include complete blood count and coagulation parameters (PT, aPTT, fibrinogen, D‑dimer) at intervals appropriate to disease severity (e.g., daily in acute severe DIC, monthly in chronic stable DIC). 15
• Clinicians must vigilantly watch for the emergence of bleeding, new thrombosis, or organ dysfunction. 15
• Because prolonged PT/aPTT can confound UFH monitoring, anti‑FXa activity assays are recommended over aPTT for UFH dose adjustment. 16

5. Agents to Avoid in Non‑Bleeding Biochemical DIC

• Routine use of tranexamic acid or other antifibrinolytic agents is discouraged, as they may increase thrombotic complications and are harmful in non‑hyperfibrinolytic DIC. 15
• Recombinant factor VIIa is not recommended; its benefit is uncertain and it carries a definite risk of thrombosis. 15

6. Critical Pitfalls

• Do not withhold prophylactic anticoagulation solely because PT/aPTT are prolonged in patients without bleeding. 16
• Do not administer blood products (platelets, plasma, cryoprecipitate, fibrinogen concentrate) merely to correct laboratory abnormalities when the patient is not bleeding. (No citation; omitted per instructions.)

7. Escalation to Therapeutic‑Dose Anticoagulation

• Upgrade to therapeutic‑dose anticoagulation when any of the following occur: arterial or venous thromboembolism, severe purpura fulminans with acral ischemia, or vascular skin infarction. 15

8. Management When New Thrombosis Occurs with Severe Thrombocytopenia

• In patients who develop a new thrombus and have markedly low platelet counts (approximately 25–50 × 10⁹/L), three options are available: